Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...
For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...
The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live ...
Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.
The drugs aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab (Kisunla) work to reduce the buildup of plaques in the ...
The nomination of Robert F. Kennedy Jr. as secretary of health and human services has sparked considerable outrage, focused ...
For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...
monoclonal antibody "LEQEMBI ®" (lecanemab) for the treatment of early Alzheimer's disease (AD)*. Eisai logo (PRNewsfoto/Eisai Inc.) ...
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...
TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...